Accéder au contenu
MilliporeSigma

Principaux documents

Voir toute la documentation

53561-U

Ascentis® Express Peptide 160 Å ES-C18 (2.7 μm) HPLC Columns

L × I.D. 15 cm × 1 mm HPLC Capillary Column

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
15 cm × 1 mm
Particle size:
2.7 μm
Matrix active group:
C18 (octadecyl) phase
Pore size:
160 Å
Matrix:
Fused-Core particle platform, superficially porous particle
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Ascentis® Express Peptide ES-C18, 2.7 μm Capillary HPLC Column, 2.7 μm particle size, L × I.D. 15 cm × 1 mm

material

stainless steel column

Quality Level

100

agency

suitable for USP L1

product line

Ascentis®

feature

endcapped: no

manufacturer/tradename

Ascentis®

packaging

1 ea of

parameter

≤100 °C temp. range

technique(s)

HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable

L × I.D.

15 cm × 1 mm

surface area

90 m2/g

impurities

<5 ppm metals

matrix

Fused-Core particle platform, superficially porous particle

matrix active group

C18 (octadecyl) phase

particle size

2.7 μm

pore size

160 Å

pH range

1-9

separation technique

reversed phase

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?

Explore all of our products under

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Protocoles

Peptide Mapping LC-MS/MS Analysis Workflow for Adalimumab

An optimized LC-MS/MS based workflow for low artifact tryptic digestion and peptide mapping of monoclonal antibody, adalimumab (Humira) using filter assisted sample preparation (FASP).

Articles

Ascentis® Express Peptide ES-C18 U/HPLC Columns

Choose Ascentis® Express Peptide ES-C18 U/HPLC Columns based on Fused-Core® technology for fast and efficient separation of high-molecular weight compounds, such as peptides and small proteins. With a 2.7 µm particle size and rigorous testing, these columns offer reliable results and high efficiency.

Quality Attribute Determination of Monoclonal Antibodies

Workflows for monoclonal antibody adalimumab characterization ensure drug safety and efficacy through critical quality attribute analysis.

Contenu apparenté

Ascentis Express Nano/Capillary Column Care and Use Sheet

Ascentis® Express Nano/Capillary Column Care & Use Sheet

Meiyun Shi et al.
Journal of separation science, 38(8), 1351-1357 (2015-01-30)
The pentapeptide thymopentin (Arg-Lys-Asp-Val-Tyr, RKDVY) corresponds to amino acids 32-36 of the 49 amino acid immunomodulatory polypeptide, thymopoietin, whose biological activity is partially reproduced. Thymopentin is widely used in the clinic and represents a promising target for drug design but
E Lesellier
Journal of chromatography. A, 1266, 34-42 (2012-11-03)
The recent introduction of new stationary phases for liquid chromatography based on superficially porous particles, called core-shell or fused-core, dramatically improved the separation performances through very high efficiency, due mainly to reduced eddy diffusion. However, few studies have evaluated the
C Gröer et al.
Journal of pharmaceutical and biomedical analysis, 100, 393-401 (2014-09-15)
Cytochrome P450 (CYP) enzymes and UDP-glucuronosyltransferases (UGT) are major determinants in the pharmacokinetics of most drugs on the market. To investigate their impact on intestinal and hepatic drug metabolism, we developed and validated quantification methods for nine CYP (CYP1A2, CYP2B6

Numéro d'article de commerce international

RéférenceGTIN
53561-U04061838531513